Subscribe to RSS
DOI: 10.1055/s-0042-1744238
Molecular Detection of Carbapenemase Enzymes Directly from Positive Blood Cultures Using Xpert Carba-R
Abstract
Objective The performance of Xpert Carba-R assay for the direct identification of carbapenemases directly from positive blood culture vials was evaluated.
Materials and Methods In total, 176 positively flagged blood culture vials, yielding carbapenem-resistant GNB (CR-GNB), were enrolled for the detection and differentiation of blaKPC, blaNDM, blaVIM, blaOXA-48, and blaIMP using Xpert Carba-R.
Results Klebsiella pneumoniae (76/176, 43.1%), Acinetobacter baumannii complex (67/176, 38%), and Escherichia coli (29/176,16.4%) were the predominant isolates. Overall, NDM production was the commonest (61/176, 34.6%), followed by the co-production of NDM + OXA-48 and the absence of any CR gene (44/176, 25%), followed by OXA-48 (27/176, 15.3%). In CR K. pneumoniae, the co-production of NDM + OXA-48 was most frequent (34/76, 44.7%), whereas in the A. baumannii complex, no CR gene was detected in the majority of isolates (38/67, 56.7%). bla NDM was the commonest gene in E. coli (18/29, 62%) and A. baumannii complex (26/67, 38.8%).
Conclusion Xpert Carba-R can identify the molecular mechanism of CR within hours after a blood culture turns positive and, thus, has the potential for optimization of antimicrobial therapy, choosing appropriate novel β-lactam combination agents, as well as infection control interventions.
Authors' Contribution
Dr. Gayatree Nayak contributed to acquisition of data, or analysis and interpretation of data, and final approval of the version to be published. Dr. Bijayini Behera contributed to conception and design, acquisition of data, or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, and final approval of the version to be published. Dr. Ashoka Mahapatra contributed to acquisition of data, or analysis and interpretation of data, and final approval of the version to be published. Dr. Swagata Tripathy contributed to conception and design, acquisition of data, and final approval of the version to be published. Mrs. Jyoti Biswal contributed to acquisition of data, and final approval of the version to be published.
Publication History
Article published online:
19 April 2022
© 2022. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Porwal R, Gopalakrishnan R, Rajesh NJ, Ramasubramanian V. Carbapenem resistant Gram-negative bacteremia in an Indian intensive care unit: a review of the clinical profile and treatment outcome of 50 patients. Indian J Crit Care Med 2014; 18 (11) 750-753
- 2 Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 2017; 215 (Suppl. 01) S28-S36
- 3 Li HH, He ZJ, Xie LM. et al. Evaluation of Xpert Carba-R assay for the detection of carbapenemase genes in gram-negative bacteria. BioMed Res Int 2021; 2021: 6614812
- 4 Cointe A, Walewski V, Hobson CA. et al. Rapid carbapenemase detection with Xpert Carba-R V2 directly on positive blood vials. Infect Drug Resist 2019; 12: 3311-3316
- 5 Rajendran S, Gopalakrishnan R, Tarigopula A. et al. Xpert Carba-R assay on flagged blood culture samples: clinical utility in intensive care unit patients with gram-negative bacteremia. Open Forum Infect Dis 2019; S2: S736-S737
- 6 Jauréguy F, Mansour H, Bigot J. et al. Use of the Xpert CarbaR assay for direct detection of carbapenemase genes from blood cultures and urine samples. J Hosp Infect 2018; 98 (03) 245-246
- 7 Mohanty S, Gajanand M, Gaind R. Identification of carbapenemase-mediated resistance among Enterobacteriaceae bloodstream isolates: a molecular study from India. Indian J Med Microbiol 2017; 35 (03) 421-425
- 8 Walia K, Madhumathi J, Veeraraghavan B. et al. Establishing antimicrobial resistance surveillance & research network in India: journey so far. Indian J Med Res 2019; 149 (02) 164-179
- 9 Veeraraghavan B, Shankar C, Karunasree S, Kumari S, Ravi R, Ralph R. Carbapenem resistant Klebsiella pneumoniae isolated from bloodstream infection: Indian experience. Pathog Glob Health 2017; 111 (05) 240-246
- 10 Singh SK, Gupta M. blaOXA-48 carrying clonal colistin resistant-carbapenem resistant Klebsiella pneumoniae in neonate intensive care unit, India. Microb Pathog 2016; 100: 75-77
- 11 Shankar C, Mathur P, Venkatesan M. et al. Rapidly disseminating blaOXA-232 carrying Klebsiella pneumoniae belonging to ST231 in India: multiple and varied mobile genetic elements. BMC Microbiol 2019; 19 (01) 137
- 12 Evans BA, Amyes SG. OXA β-lactamases. Clin Microbiol Rev 2014; 27 (02) 241-263
- 13 Veeraraghavan B, Pragasam AK, Bakthavatchalam YD. et al. Newer β-lactam/β-lactamase inhibitor for multidrug-resistant gram-negative infections: challenges, implications and surveillance strategy for India. Indian J Med Microbiol 2018; 36 (03) 334-343